News
GenSight Biologics Announces the Filing of its 2023 Universal Registration Document
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Sartorius Stedim Biotech publishes unaudited first quarter results for 2024
La Gran Carpa Catedral Reaches New Audiences Across Europe and MENA Thanks to Eutelsat Group Satellite Coverage
Eutelsat Group (ISIN: FR0010221234 - Euronext Paris / London Stock Exchange: ETL) announces a new multi-year partnership with Puerto Rico-based La Gran Carpa Catedral (LGCC), a non-profit
Kaufman & Broad SA: AVAILABILITY OF THE PREPARATORY DOCUMENTS FOR THE COMBINED ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 2024, MAY 6TH
Sensorion Announces its Participation in the Van Lanschot Kempen's Life Sciences Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
EQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies
GenSight Biologics Reports Cash Position as of March 31, 2024, and Provides Business Update
Regulatory News:
GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing
Bureau Veritas Undertakes a Buyback of c.0.8% of Its Shares Under the Accelerated Placement Announced by Wendel
Bureau Veritas, a global leader in the Testing, Inspection and Certification (TIC) industry, today announces its decision to acquire from Wendel a block of its own shares – which will amount to a
GenSight Biologics Announces its 2024 Financial Calendar
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Prodware: Strong increase in Current Operating Income: €49.1 million (+68%) - Net Profit impacted by exceptional items
Pernod Ricard Rated Top European Company in the 2024 Data & AI Human Capital Report: World Rankings Compiled by AlixPartners & Darwin X
Regulatory News:
Press release – Paris, 4 April 2024
Pernod Ricard (Paris:RI) has been ranked as the leading European, and number four in the world, consumer goods company in terms of
BILENDI: Bilendi now offers BARI, the AI-powered research assistant, for quantitative projects
BILENDI: Results for the 2023 financial year: marked improvement in profitability in the second half of 2023
ESI Group und FAW-Volkswagen TE bauen strategische Partnerschaft zur Förderung intelligenter Simulationstechnologie im Automobilbereich auf
ESI Group (Paris:ESI) und FAW-Volkswagen (FAW-VW) TE haben im Zusammenhang mit der Unterzeichnung eines Memorandum of Understanding (MoU) zur Förderung der intelligenten Simulationstechnologie in
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
ESI Group and FAW-Volkswagen TE Forge Strategic Partnership to Advance Automotive Intelligent Simulation Technology
Regulatory News:
ESI Group (Paris:ESI) and FAW-Volkswagen (FAW-VW) TE have commemorated their strategic partnership with the signing of a Memorandum of Understanding (MoU) aimed at advancing
EQS-News: Abivax reports 2023 financial results and operational update
Successful Launch of EUTELSAT 36D Satellite
Regulatory News:
Eutelsat Group (ISIN: FR0010221234 - Euronext Paris / London Stock Exchange: ETL) today announces the successful launch and deployment of its EUTELSAT 36D satellite. SpaceX’s
Poxel to Report Its 2023 Annual Results by the End of April 2024
Regulatory News:
POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic
Kaufman & Broad SA: AVAILABILITY OF THE 2023 UNIVERSAL REGISTRATION DOCUMENT
RALLYE S.A.: Restructuring of Casino Liquidation of holding companies